Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

630
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
630
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024.

JCO oncology practice·2026
Same author

The timeliness of health plan drug coverage policy changes to FDA label revisions.

Health affairs scholar·2026
Same author

FDA approvals of specialty drugs, 2000-2024.

Health affairs scholar·2026
Same author

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings.

Health affairs scholar·2025
Same author

Estimating the societal economic burden of food allergy in the United States.

Journal of medical economics·2025
Same author

State-level opportunities to advance biomarker testing in patients with advanced cancers and state-regulated plans.

Future oncology (London, England)·2025

Related Experiment Video

Updated: Jan 9, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K

Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway.

Tu My To1, Stacey Kowal1, James D Chambers2

  • 1Genentech, Inc, South San Francisco, California.

Cancer Research Communications
|December 1, 2025
PubMed
Summary

The accelerated approval (AA) pathway for cancer drugs shows positive real-world outcomes. Most AA indications improved survival, with significant gains in progression-free survival and overall survival for many patients.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Related Experiment Videos

Last Updated: Jan 9, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Area of Science:

  • Oncology
  • Health Economics
  • Real-World Evidence

Background:

  • The accelerated approval (AA) pathway aims to speed up access to novel cancer therapies for patients with unmet medical needs.
  • Limited real-world data exists on the clinical effectiveness and population-level impact of drugs approved via the AA pathway in solid tumors.

Purpose of the Study:

  • To assess the real-world clinical outcomes of accelerated approval (AA) drugs in patients with solid tumors.
  • To evaluate the population-level health gains associated with AA cancer medications.

Main Methods:

  • Utilized a nationwide electronic health record (EHR)-derived de-identified database (2011-2023) for patients with selected solid tumors.
  • Compared outcomes between patients receiving AA products and non-AA products with the same indication.
  • Assessed real-world progression-free survival (rwPFS), overall survival (OS), market share, real-world progression-free life years (rwPFLYs), and life years (LYs).

Main Results:

  • Of 23 studied AA indications, 83% had verified clinical benefit; 17% were withdrawn.
  • Overall, 78% of AA indications showed significant rwPFS or OS improvements, with none showing worse outcomes.
  • AA drugs provided an estimated 56,399 rwPFLYs and 50,848 LYs gained among 118,107 patients treated during their AA window.

Conclusions:

  • Most accelerated approval indications in solid tumors are linked to improved clinical outcomes and substantial population health gains.
  • The study suggests the AA pathway effectively targets beneficial therapies, but may require expanded evidence beyond traditional endpoints for verification, especially for rare tumors.
  • Real-world data analysis is crucial for understanding the true impact of expedited drug approval programs.